Linked Life Data

18006775

Source:http://linkedlifedata.com/resource/pubmed/id/18006775

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
22 Pt 1
pubmed:dateCreated
2007-11-16
pubmed:abstractText
Hepatocyte growth factor (HGF/SF) and its receptor c-Met have previously been shown to be up-regulated in multiple human cancers, including glioblastoma multiforme. To better understand if AMG 102, a fully human, anti-HGF/SF-neutralizing antibody, could be incorporated into current clinical practice, AMG 102 was tested preclinically in combination with temozolomide or docetaxel to determine if enhanced efficacy was observed compared with AMG 102 alone.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6735-42
pubmed:dateRevised
2009-11-5
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts.
pubmed:affiliation
Department of Oncology Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91362, USA. tjun@amgen.com
pubmed:publicationType
Journal Article